Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Alveolar Bone Loss
Interventions: INFUSE® Bone Graft; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Greenwood Village, Colorado • Sarasota, Florida + 4 more

Conditions: Acetaminophen Overdose
Interventions: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Orange, California + 11 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: abatacept, Methotrexate (MTX); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more

Conditions: Type 2 Diabetes
Interventions: Exercise program, Ascorbic Acid (Vitamin C); Behavioral · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Interventions: [68Ga]Ga-NNS309, [177Lu]Lu-NNS309; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more

Conditions: Meningococcal Disease
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 7 Years to 15 Years
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more

Conditions: Multiple Myeloma
Interventions: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL); Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Fatigue, Neoplasms
Interventions: dexmethylphenidate(d-mph); Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 21
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Tucson, Arizona + 17 more

Conditions: Pure Autonomic Failure, Multiple System Atrophy
Interventions: Magnetic Resonance Spectroscopy Imaging; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Renal Dialysis
Interventions: BAY1213790, 0.9% sodium chloride solution; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more

Conditions: Carcinoma, Hepatocellular
Interventions: pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia
Interventions: Clinical Learning Study smartphone app (i.e., the study app); Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Anaheim, California • Torrance, California • Hialeah, Florida + 4 more

Conditions: Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism, Pulmonary Thromboembolism
Interventions: recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 22
States / cities: Montgomery, Alabama • Modesto, California • Stanford, California + 18 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Palbociclib, Carboplatin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Parkinson's Syndrome
Interventions: NAV5001, DaTscan; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Orlando, Florida

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more

Conditions: Alzheimer Disease
Interventions: LY3954068, Placebo, Flortaucipir F18; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more

Conditions: Normal Hepatic Function, Impaired Hepatic Function
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Anaheim, California • Coral Gables, Florida • Orlando, Florida

Conditions: Multiple Myeloma
Interventions: Elranatamab-bcmm, Cyclophosphamide; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Acne Vulgaris
Interventions: Visonac PDT, Vehicle cream with PDT; Drug
Lead sponsor: Photocure; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Oceanside, California • San Diego, California • Jacksonville, Florida + 12 more

Conditions: Diabetic Foot
Interventions: SkinTE, Control; Biological · Other
Lead sponsor: PolarityTE; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 23
States / cities: Mesa, Arizona • Castro Valley, California • Fresno, California + 19 more

Conditions: Hepatitis C, Chronic
Interventions: Interleukin 28B testing; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Sepsis
Interventions: Intravenous GR270773- Phospholipid Emulsion, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 132
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more

Conditions: Leber Congenital Amaurosis
Interventions: AAV RPE65; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Localized Alveolar Ridge Augmentation With Space Maintenance Devices

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Magnetic Resonance Spectroscopy in Autonomic Failure

End-stage Renal Disease (ESRD) Pilot Study

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)